

MicroRNA Modification of Coxsackievirus B3 Decreases Its Toxicity, while Retaining Oncolytic Potency against Lung Cancer

Huitao Liu, Yuan Chao Xue, Haoyu Deng, Yasir Mohamud, Chen Seng Ng, Axel Chu, Chinten James Lim, William W. Lockwood, William W.G. Jia, and Honglin Luo

Correspondence: honglin.luo@hli.ubc.ca
<https://doi.org/10.1016/j.omto.2020.12.002>

(Mol. Ther. Oncolytics 16, 207–218; March 27, 2020)

In the originally published version of this article, we made errors regarding the titer of coxsackievirus B3 during TCID50 calculation. The dose of virus used for the animal study was 1×10^6 PFU instead of 1×10^8 PFU, and, in Figures 5A and 5C, all the virus titers need to be divided by 100. The corrected Figure 5 is provided below.

The authors regret this error.




Figure 5. RNA Levels and Titers of miR-CVB3 Are Significantly Reduced in Normal Lung Epithelial Cells and Cardiomyocytes Compared to WT-CVB3 (Corrected)






Figure 5. RNA Levels and Titers of miR-CVB3 Are Significantly Reduced in Normal Lung Epithelial Cells and Cardiomyocytes Compared to WT-CVB3 (Original)